The medication has a half-life of approximately one week, and the FDA guidance ensures adequate clearance before conception to minimize any potential fetal exposure during early pregnancy, when organogenesis occurs
Once-weekly administered tirzepatide proved to be both noninferior and superior in reducing glycosylated hemoglobin levels in T2DM patients and demonstrated robust weight loss in obese patients [27,28]
Conclusion Retatrutide and CagriSema represent the next generation of obesity pharmacotherapy
Liu J, Tang H, Chen F, Li C, Xie Y, Kang R, et al
[14] [5] Underlying health conditions such as hypothyroidism, polycystic ovary syndrome (PCOS), Cushing's syndrome, and insulin resistance or type 2 diabetes can independently drive weight gain and should be assessed and managed if not already addressed
Demand Outlook After the Reclassification The February 2026 reclassification has direct procurement implications for B2B buyers